References:
1)https://www.worldometers.info/coronavirus/country/india/ [Accessed on 4th June 2021]
2)https://www.unicef.org/india/coronavirus/covid-19/covid-19-and-children [ Accessed on 4th June 2021].
3)Graff, Kelly, Smith et al. Risk Factors for Severe COVID-19 in Children. The Pediatric Infectious Disease Journal 2021; 40 :137-145
4)Millen GC, Arnold R, Cazier JB etal. Severity of COVID-19 in children with cancer: Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project. Br J Cancer 2021 ;124:754-759. doi: 10.1038/s41416-020-01181-0.
5)Madhusoodhan PP, Pierro J, Musante J, et al. Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience. Pediatr Blood Cancer 2021;68:e28843.
6)Ahmad N, Essa MF, Sudairy R. Impact of Covid19 on a tertiary care pediatric oncology and stem cell transplant unit in Riyadh, Saudi Arabia. Pediatr Blood Cancer 2020; 9:e28560. doi: 10.1002/pbc.28560
7)Meena JP, Kumar Gupta A, Seth R etal. Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review. Pediatr Blood Cancer 2021;68(6):e29005. doi: 10.1002/pbc.29005.
8)Dorantes-Acosta E, Ávila-Montiel D, Klünder-Klünder M etal . Survival and Complications in Pediatric Patients With Cancer and COVID-19: A Meta-Analysis. Front Oncol 2021; 10:608282. doi: 10.3389/fonc.2020.608282.
9)Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020;145:e20200702.
10)André, N., Rouger-Gaudichon, J., Brethon et al. COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: high risk of severe forms? Pediatr. Blood Cancer 2020; 67: e28392
11)Ferrari, A., Zecca, M., Rizzari, C et al. Children with cancer in the time of COVID-19: an 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy. Pediatr. Blood Cancer 2020; 67, e28410
12)Cornelius J Clancy, Ilan S Schwartz, Brittany Kula et al. Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. Open Forum Infectious Diseases 2021; 8;3
13)Musuuza JS, Watson L, Parmasad V et al. (2021) Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLOS ONE 2016;5: e0251170.
14)Ramaswamy A, Nayak L, Roy Moulik N et al. COVID-19 in cancer patients on active systemic therapy - Outcomes from LMIC scenario with an emphasis on need for active treatment. Cancer Med. 2020 ;9(23):8747-8753. doi: 10.1002/cam4.3423.
15)Teresa Aydillo, Ana S et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med 2020; 383:2586-2588